Expanded Testing to Assess Immunogenicity in Biologics Now Offered
June 9, 2010 - Charles River Biopharmaceutical Services (BPS) has experience developing, validating and implementing in vivo, in vitro and ex vivo assays to study immunogenicity and biological potency. To address the evolving needs of our customers, we are expanding our existing immunogenicity portfolio of in vivo immunopotency assays, ELISAs and cell-based assays to include cell-based neutralizing assays.
Cell-based neutralizing assays can be used to detect the presence of anti-drug antibodies that can interfere with the drugs’ effectiveness, an important consideration in immunogenicity risk assessment. These assays can also be utilized in the optimization of biologics and biosimilars during both preclinical and clinical investigations. We will work closely with customers to assist in the transfer, development and validation of these types of assays in a GxP-compliant manner.
For more information about this new immunogenicity assay or to learn more about the variety of other services BPS provides, please email askcharlesriver@crl.com or call 1-877-CRIVER-1.
Related Information